Oncotelic extends JV term sheet standstill with GMP to March 31, 2022

Oncotelic Therapeutics, Inc.

Extended standstill provisions of JV term sheet with Golden Mountain Partners to March 31, 2022.
JV intended to develop Oncotelic's drug portfolio and build a manufacturing facility.
Company previously announced plan to take the JV public via IPO at a future date.
Extension allows additional time to complete the transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.